HENDERSON, NV--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCQB:RBCC) is heeding an urgent call to action put out by a prominent group of medical scientists looking to end the nation’s expanding prescription opioid addiction epidemic – a problem that is now claiming an average of 44 lives per day.
Researchers at the noted Johns Hopkins Bloomberg School of Public Health have recently issued a set of far-reaching recommendations designed to cut prescription opioid addictions. These recommendations primarily advocate, among other suggestions, new ways to dispense and monitor opioid prescriptions, and changes to how those with addictions are identified and treated.
“These sterling recommendations are a much-needed and long overdue step in the right direction,” said RBCC CEO Kimberly Palmer. “We look forward to helping implement these common sense recommendations and will work with anyone interested to see they become a reality as quickly as possible. RBCC is dedicated to eradicating opioid addiction, which is why we are working hard to ensure the anti-addiction drug Naltrexone is made available to treatment centers and groups. And it’s why we are striving to develop a system of inclusive, low-cost treatment programs ourselves to help those least able to afford costly care.”
Properly used, opioids provide much-needed pain relief for patients suffering acute pain. However, opioids are prone to abuse and addiction, often with tragic results.
According to the Centers for Disease Control, nearly 23,000 individuals died in 2013 as a result of being hooked on opioids (painkilling drugs) – four times the number who died in 1999. Over that time, prescription opioid sales have increased 300 percent.
For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
